Identification and Predictive Analysis of Revenue Determinants in the Pharma Industry: A Longitudinal Analysis of Financial, Regulatory and Pipeline Data

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Rusne Sipelyte, Athina Marina Metaxa
{"title":"Identification and Predictive Analysis of Revenue Determinants in the Pharma Industry: A Longitudinal Analysis of Financial, Regulatory and Pipeline Data","authors":"Rusne Sipelyte,&nbsp;Athina Marina Metaxa","doi":"10.1007/s12247-025-09975-6","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Maintaining positive revenue performance and R&amp;D productivity is crucial for the pharma industry, therefore identifying and predicting future revenue determinants is of upmost importance. The aim of the study was to identify factors that determine annual revenue and to use these factors to develop a model that predicts future revenues.</p><h3>Methods</h3><p>IDEA Pharma’s longitudinal Pharmaceutical Innovation and Invention Index data were used to conduct the analyses, looking at the financial, regulatory and pipeline data (2019–2023) of the top 24 pharmaceutical companies. Broader industry trends over the last 5 years were analysed using descriptive statistics. To validate the factors gleaned from the descriptive statistics, a predictive model was constructed. This was done through predictive statistical analysis (stepwise regression), producing a model that can predict future revenue.</p><h3>Results</h3><p>Three factors were determined to be significant determinants of higher future revenues: higher R&amp;D spend, lower R&amp;D spend as a proportion of current revenue, and higher number of Phase III clinical trials.</p><h3>Conclusions</h3><p>The resulting model combined financial, commercial, and strategic metrics from the world’s largest pharmaceutical companies to produce a statistically robust method of predicting revenues, that is critical for every pharma company’s growth and strategic planning.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12247-025-09975-6.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-09975-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Maintaining positive revenue performance and R&D productivity is crucial for the pharma industry, therefore identifying and predicting future revenue determinants is of upmost importance. The aim of the study was to identify factors that determine annual revenue and to use these factors to develop a model that predicts future revenues.

Methods

IDEA Pharma’s longitudinal Pharmaceutical Innovation and Invention Index data were used to conduct the analyses, looking at the financial, regulatory and pipeline data (2019–2023) of the top 24 pharmaceutical companies. Broader industry trends over the last 5 years were analysed using descriptive statistics. To validate the factors gleaned from the descriptive statistics, a predictive model was constructed. This was done through predictive statistical analysis (stepwise regression), producing a model that can predict future revenue.

Results

Three factors were determined to be significant determinants of higher future revenues: higher R&D spend, lower R&D spend as a proportion of current revenue, and higher number of Phase III clinical trials.

Conclusions

The resulting model combined financial, commercial, and strategic metrics from the world’s largest pharmaceutical companies to produce a statistically robust method of predicting revenues, that is critical for every pharma company’s growth and strategic planning.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmaceutical Innovation
Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-
CiteScore
3.70
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信